Iovance Biotherapeutics (IOVA)

Executive Summary

Iovance Biotherapeutics is a commercial-stage biotechnology company pioneering tumor-infiltrating lymphocyte (TIL) therapy for solid tumors. Its lead product, Amtagvi™ (lifileucel), received FDA accelerated approval in February 2024 for advanced melanoma, marking the first-ever approved TIL therapy. The company is now focused on expanding Amtagvi into earlier treatment lines and additional indications, while advancing a robust pipeline of novel TIL and TCR-T therapies. Key pipeline assets include LN-145 for non-small cell lung cancer and endometrial cancer, IOV-3001 (a next-generation TIL) for melanoma, and various combination regimens with checkpoint inhibitors. Iovance has established manufacturing capabilities for individualized TIL therapies and is investing in process improvements to enhance scalability and cost efficiency. The company’s commercial launch of Amtagvi is progressing, with growing physician adoption and reimbursement coverage. Financially, Iovance is well-capitalized to support its clinical development and commercial infrastructure. The company’s platform technology holds promise across multiple solid tumors, underpinned by durable responses observed in clinical trials. With a first-mover advantage in TIL therapy, Iovance is positioned to address significant unmet need in oncology. Near-term value drivers include clinical data readouts in endometrial cancer and frontline melanoma, as well as regulatory progress in earlier treatment settings.

Upcoming Catalysts (preview)

• Q1 2027Phase 3 TILVANCE-301 interim analysis in frontline metastatic melanoma60% success
• H2 2026Phase 2 data readout for lifileucel in endometrial cancer (NCT06481592)50% success
• H1 2027Initial clinical data for next-gen TIL IOV-3001 in melanoma (Phase 1/2)40% success